18F-FACBC PET/CT FOR STAGING HIGH RISK PROSTATE CANCER - FACBC-STAGING-2014

AOU di Bologna Policlinico S.Orsola-Malpighi0 个研究点目标入组 110 人开始时间: 2014年8月27日最近更新: 2018年2月26日

适应症

试验速览

暂无简介。

•1.Subjects with biopsy-proven adenocarcinoma of the prostate
•2.Moderate- to high risk prostate cancer as defined by:
•-Moderate risk: T2b-T2c or Gleason score 7 or PSA 10-20 ng/mL;
•-High risk: T3a or Gleason score 8-10 or PSA > 20 ng/mL.
•3. Staging according to conventional preoperative workup tests (digital rectal examination, transrectal ultrasound, biopsy, likelihood of lymph node metastasis with clinical nomograms, Choline PET/CT)
•4. Choline PET/CT negative for bone metastases
•5.Surgical plan: prostatectomy with limited or extended lymph node dissection within 40 days from the imaging
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 55
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 55

•1.Inability to undergo 18F-FACBC PET/CT scanning for any reason.
•2.Prior invasive malignancy (except basal cell carcinoma) unless disease-free for a minimum of 3 years
•3.Severe acute co-morbidity
•4.Specific preoperative therapy (hormonal treatment, chemotherapy, radiotherapy

发起方

AOU di Bologna Policlinico S.Orsola-Malpighi